Technology and Biotech Lead as US Stocks Show Mixed Performance

Ramit Sethi

Author of "I Will Teach You to Be Rich," focusing on psychology and systems for a rich life without guilt.

This article provides an overview of significant movements in the US stock market on a recent Friday, focusing on companies that experienced notable gains despite a general market decline. It highlights key factors contributing to these individual stock surges, including strong financial results, strategic acquisitions, and positive industry developments.

Market Highlights: Resilience Amidst Fluctuation

US Stock Market Takes a Hit

On Friday, the overall US stock market faced considerable pressure, with the Dow Jones index registering a substantial decline of approximately 500 points, signaling a challenging trading day for many investors.

Marvell Technology's Impressive Performance

Amidst the broader market's struggles, shares of Marvell Technology Inc. experienced a significant ascent. The company's stock jumped by 18.4%, closing at $89.56, following the release of its fourth-quarter financial results. Marvell surpassed revenue expectations, reporting $2.22 billion against an estimated $2.21 billion, and delivered adjusted earnings of 80 cents per share, exceeding forecasts by a single cent.

Notable Gainers in a Down Market

While the market generally trended downwards, several companies bucked the trend with impressive gains. Day One Biopharmaceuticals Inc. saw its shares skyrocket by 65.8% to $21.18 after announcing its acquisition by Servier. Battalion Oil Corp. increased by 33.8% to $25.44, buoyed by a sector-wide rally in oil and gas, attributed to geopolitical developments. Red Cat Holdings Inc. surged by 21.9% to $18.41, and Tevogen Bio Holdings Inc. rose by 20.2% to $9.32.

Strong Earnings Drive Other Companies Up

Smith & Wesson Brands Inc. also posted strong gains, climbing 18.4% to $13.96 after reporting better-than-expected third-quarter financial results and issuing optimistic fourth-quarter sales guidance. Gevo Inc. appreciated by 18% to $2.23, thanks to a narrower-than-anticipated quarterly loss. Uniqure NV's stock increased by 17.6% to $12.53. Additionally, Samsara Inc. saw its shares jump by 15.4% to $34.16 after exceeding fourth-quarter financial expectations and providing strong FY27 guidance.

Diverse Factors Contributing to Growth

Other companies also contributed to the day's positive outliers. Texxon Holding Ltd. gained 14.3% to $21.89, and Solid Biosciences Inc. rose 12.7% to $6.32 following an oversubscribed private placement of $240 million. Applied Optoelectronics Inc. improved by 11.6% to $112.88, while Planet Labs PBC went up by 10.2% to $27.09. Ondas Inc. increased by 9.2% to $11.42, driven by significant orders for its counter-UAS systems from the Middle East. Karman Holdings Inc. saw a 7.3% increase to $104.07 after an analyst upgrade from Piper Sandler. CF Industries Holdings, Inc. and Intuitive Machines Inc. also recorded gains of 7.2% and 6.7% respectively. Finally, JD.Com Inc. closed up by 5.6% at $26.90.

you may like

youmaylikeicon
Unlocking Wealth: Warren Buffett's Dividend Strategy for Financial Growth

Unlocking Wealth: Warren Buffett's Dividend Strategy for Financial Growth

By Bola Sokunbi
Greencoat UK Wind's Resilience Amidst Sector Headwinds

Greencoat UK Wind's Resilience Amidst Sector Headwinds

By Bola Sokunbi
BigCommerce Strategic Shift: AI, Monetization, and Platform Evolution

BigCommerce Strategic Shift: AI, Monetization, and Platform Evolution

By Vicki Robin
Amending Your Tax Return: A Comprehensive Guide to Form 1040-X

Amending Your Tax Return: A Comprehensive Guide to Form 1040-X

By Mr. Money Mustache
South Bow Reports Robust Q4 and Full-Year 2025 Financial Results and Operational Milestones

South Bow Reports Robust Q4 and Full-Year 2025 Financial Results and Operational Milestones

By T. Harv Eker
RBC Capital Adjusts Price Target for Viridian Therapeutics to $42, Maintains Outperform Rating

RBC Capital Adjusts Price Target for Viridian Therapeutics to $42, Maintains Outperform Rating

By Dave Ramsey
Truist Elevates Price Target and Maintains Buy Rating for BridgeBio Pharma (BBIO)

Truist Elevates Price Target and Maintains Buy Rating for BridgeBio Pharma (BBIO)

By Dave Ramsey
Analysts Revise Forecasts for Guidewire Software After Strong Q2 Performance

Analysts Revise Forecasts for Guidewire Software After Strong Q2 Performance

By Bola Sokunbi
WEX: A Robust Payments Company with Undervalued Potential

WEX: A Robust Payments Company with Undervalued Potential

By Dave Ramsey
Micron Technology Stock Performance and Market Outlook

Micron Technology Stock Performance and Market Outlook

By Bola Sokunbi
New Tariffs by Trump Administration Insufficient to Cover Revenue Shortfall

New Tariffs by Trump Administration Insufficient to Cover Revenue Shortfall

By Natalie Pace
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly

Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly

By JL Collins
Top 3 Industrials Stocks Poised for March Surge

Top 3 Industrials Stocks Poised for March Surge

By Ramit Sethi
FuelCell Energy's Q1 Earnings Preview: Analyst Revisions and Market Expectations

FuelCell Energy's Q1 Earnings Preview: Analyst Revisions and Market Expectations

By Natalie Pace
Smith & Wesson Shares Surge on Strong Q3 Results; Premarket Movers Overview

Smith & Wesson Shares Surge on Strong Q3 Results; Premarket Movers Overview

By Bola Sokunbi